Core Viewpoint - The company has signed a new drug technology transfer contract with its affiliate, with a total transaction amount of 20 million yuan [1] Group 1: Transaction Details - The company has entered into a technology transfer agreement for the NeoAB33 new drug project with its affiliate, Huada Protein, for a total of 20 million yuan [1] - The transaction is classified as a related party transaction due to the involvement of the company's chairman, general manager, and chief engineer in Huada Protein's management [1] Group 2: Strategic Implications - The acquisition of the relevant technology will accelerate the development of the company's protein/antibody drug platform, enhancing its capabilities from molecular design to cell line construction [1] - The company aims to expand its pipeline reserves in the cardiovascular field, promoting a differentiated competitive layout in this niche market and accelerating the transformation of research and development results [1]

Core Viewpoint - The company has signed a technology transfer agreement with its affiliate, BGI Protein, for the NeoAB33 new drug project, with a total transaction amount of 20 million yuan, which constitutes a related party transaction [1] Group 1: Transaction Details - The transaction involves the transfer of detailed technical materials, technical details, and related documents for the NeoAB33 project, including constructed cell lines and related research, characterization analysis, preliminary pharmaceutical and immunological studies, initial process research, and preliminary quality research technical materials, along with all original records in both written and electronic formats [1] - The agreement is based on an assessment result, ensuring that the pricing is fair and reasonable after sufficient communication between the parties involved [1] Group 2: Strategic Implications - This transaction will help the company accelerate the construction of its protein/antibody drug platform, expand its pipeline reserves in the cardiovascular field, and promote differentiated competitive layout in this niche market [1] - The agreement is expected to facilitate the transformation of research and development results, achieve technological complementarity and resource integration, and support the improvement of the company's innovative drug research and development system and market competitiveness [1]